242 related articles for article (PubMed ID: 30408108)
1. Vulnerable combinations of functional dopaminergic polymorphisms to late-onset treatment resistant schizophrenia.
Oishi K; Kanahara N; Takase M; Oda Y; Nakata Y; Niitsu T; Ishikawa M; Sato Y; Iyo M
PLoS One; 2018; 13(11):e0207133. PubMed ID: 30408108
[TBL] [Abstract][Full Text] [Related]
2. Epistatic effect of Ankyrin repeat and kinase domain containing 1 - Dopamine receptor D2 and catechol-o-methyltransferase single nucleotide polymorphisms on the risk for hazardous use of alcohol in Lithuanian population.
Kaminskaite M; Jokubka R; Janaviciute J; Lelyte I; Sinkariova L; Pranckeviciene A; Borutaite V; Bunevicius A
Gene; 2021 Jan; 765():145107. PubMed ID: 32889058
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia.
Terzić T; Kastelic M; Dolžan V; Plesničar BK
Psychiatr Danub; 2016 Jun; 28(2):127-31. PubMed ID: 27287786
[TBL] [Abstract][Full Text] [Related]
4. Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosis.
Yamanaka H; Kanahara N; Suzuki T; Takase M; Moriyama T; Watanabe H; Hirata T; Asano M; Iyo M
Schizophr Res; 2016 Feb; 170(2-3):252-8. PubMed ID: 26775264
[TBL] [Abstract][Full Text] [Related]
5. Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia.
Oda Y; Kanahara N; Iyo M
Int J Mol Sci; 2015 Dec; 16(12):30144-63. PubMed ID: 26694375
[TBL] [Abstract][Full Text] [Related]
6. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis.
Kimura H; Kanahara N; Komatsu N; Ishige M; Muneoka K; Yoshimura M; Yamanaka H; Suzuki T; Komatsu H; Sasaki T; Hashimoto T; Hasegawa T; Shiina A; Ishikawa M; Sekine Y; Shiraishi T; Watanabe H; Shimizu E; Hashimoto K; Iyo M
Schizophr Res; 2014 May; 155(1-3):52-8. PubMed ID: 24667073
[TBL] [Abstract][Full Text] [Related]
7. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia.
Suzuki T; Kanahara N; Yamanaka H; Takase M; Kimura H; Watanabe H; Iyo M
Psychiatry Res; 2015 Jun; 227(2-3):278-82. PubMed ID: 25863824
[TBL] [Abstract][Full Text] [Related]
8. Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms.
Gupta M; Chauhan C; Bhatnagar P; Gupta S; Grover S; Singh PK; Purushottam M; Mukherjee O; Jain S; Brahmachari SK; Kukreti R
Pharmacogenomics; 2009 Feb; 10(2):277-91. PubMed ID: 19207030
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic pathway gene polymorphisms and genetic susceptibility to schizophrenia among north Indians.
Srivastava V; Deshpande SN; Thelma BK
Neuropsychobiology; 2010; 61(2):64-70. PubMed ID: 20016224
[TBL] [Abstract][Full Text] [Related]
10. The effect of rs1076560 (DRD2) and rs4680 (COMT) on tardive dyskinesia and cognition in schizophrenia subjects.
Punchaichira TJ; Kukshal P; Bhatia T; Deshpande SN; Thelma BK
Psychiatr Genet; 2020 Oct; 30(5):125-135. PubMed ID: 32931693
[TBL] [Abstract][Full Text] [Related]
11. The impacts of dopamine D2 receptor polymorphism and antipsychotic dosage on dopamine supersensitivity psychosis in schizophrenia.
Takase M; Kanahara N; Oda Y; Niitsu T; Watanabe H; Iyo M
Schizophr Res; 2017 Dec; 190():182-183. PubMed ID: 28285026
[No Abstract] [Full Text] [Related]
12. Impact of DRD2/ANKK1 and COMT Polymorphisms on Attention and Cognitive Functions in Schizophrenia.
Nkam I; Ramoz N; Breton F; Mallet J; Gorwood P; Dubertret C
PLoS One; 2017; 12(1):e0170147. PubMed ID: 28085950
[TBL] [Abstract][Full Text] [Related]
13. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment.
Gupta M; Bhatnagar P; Grover S; Kaur H; Baghel R; Bhasin Y; Chauhan C; Verma B; Manduva V; Mukherjee O; Purushottam M; Sharma A; Jain S; Brahmachari SK; Kukreti R
Pharmacogenomics; 2009 Mar; 10(3):385-97. PubMed ID: 19290789
[TBL] [Abstract][Full Text] [Related]
14. Risk Genes in Schizophrenia and Their Importance in Choosing the Appropriate Antipsychotic Treatment.
Werner FM; Coveñas R
Curr Pharm Des; 2021 Oct; 27(30):3281-3292. PubMed ID: 33588721
[TBL] [Abstract][Full Text] [Related]
15. Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.
Nakata Y; Kanahara N; Iyo M
J Psychopharmacol; 2017 Dec; 31(12):1511-1518. PubMed ID: 28925317
[TBL] [Abstract][Full Text] [Related]
16. Association of Genetic Variants of Dopamine and Serotonin In Schizophrenia.
Zakharyan R; Ghazaryan H; Kocourkova L; Chavushyan A; Mkrtchyan A; Zizkova V; Arakelyan A; Petrek M
Arch Med Res; 2020 Jan; 51(1):13-20. PubMed ID: 32086104
[TBL] [Abstract][Full Text] [Related]
17. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
[TBL] [Abstract][Full Text] [Related]
18. Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.
Zhang JP; Robinson DG; Gallego JA; John M; Yu J; Addington J; Tohen M; Kane JM; Malhotra AK; Lencz T
Schizophr Bull; 2015 Nov; 41(6):1248-55. PubMed ID: 26320194
[TBL] [Abstract][Full Text] [Related]
19. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.
Kimura H; Kanahara N; Sasaki T; Komatsu N; Ishige M; Muneoka K; Ino H; Yoshimura K; Yamanaka H; Suzuki T; Komatsu H; Watanabe H; Shimizu E; Iyo M
J Psychopharmacol; 2016 Aug; 30(8):795-802. PubMed ID: 27371496
[TBL] [Abstract][Full Text] [Related]
20. A novel DRD2 single-nucleotide polymorphism associated with schizophrenia predicts age of onset: HapMap tag-single-nucleotide polymorphism analysis.
Voisey J; Swagell CD; Hughes IP; Lawford BR; Young RM; Morris CP
Genet Test Mol Biomarkers; 2012 Feb; 16(2):77-81. PubMed ID: 21861710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
